In another study, temozolomide (TMZ), which is the most frequently used drug for metastatic melanoma patients, showed an increase in T cell infiltration in mouse models of transplanted melanoma and genitourinary tumors, but despite a similar increase in CXCL9 and CXCL10 in all sites after TMZ exposure, no increased infiltration of T cells was seen in the cutaneous tumor. This evidence concerns the gene CXCL9 and melanoma.